Skip to main content
. 2023 May 31;30(2):167–177. doi: 10.11005/jbm.2023.30.2.167

Table 1.

General characteristics of the study patients and comparison between the sexes

Variables Sample Men Women P-value
NYHA functional class (N=109)
 I or II 36 (33.0) 22 (40.7) 14 (25.5) 0.090a)
 III or IV 73 (67.0) 32 (59.3) 41 (74.5)

LVEF (N=109)
 HFpEF 53 (48.6) 24 (44.4) 29 (52.7) 0.642a)
 HFmrEF 12 (11.0) 7 (13.0) 5 (9.1)
 HFrEF 44 (40.4) 23 (42.6) 21 (38.2)

HF etiology (N=109)
 Ischemic 63 (57.8) 31 (57.4) 32 (58.2) 0.935a)
 Non-ischemic 46 (42.2) 23 (42.6) 23 (41.8)

Glycemic status (N=109)
 Normoglycemic 22 (20.2) 10 (18.5) 12 (21.8) 0.550a)
 Prediabetes 35 (32.1) 20 (37.0) 15 (27.3)
 Diabetes 52 (47.7) 24 (44.4) 28 (50.9)

BMD (N=109)
 Normal bone mass 49 (45.0) 28 (51.9) 21 (38.2) 0.335a)
 Osteopenia 43 (39.4) 18 (33.3) 25 (45.5)
 Osteoporosis 17 (15.6) 8 (14.8) 9 (16.4)

TBS (N=57)
 Normal microarchitecture 36 (63.2) 15 (65.2) 21 (61.8) 0.736b)
 Partial bone degradation 8 (14.0) 4 (17.4) 4 (11.8)
 Bone degradation 13 (22.8) 4 (17.4) 9 (26.5)

History of osteoporotic fractures (N=109) 6 (5.5) 3 (5.6) 3 (5.5) 1.000b)

Osteoporosis (BMD or fractures) (N=109) 23 (21.1) 11 (20.4) 12 (21.8) 0.853a)

Vitamin D deficiency (N=90) 31 (34.4) 9 (23.1) 22 (43.1) 0.047a)

History of alcohol consumption (N=109) 54 (49.5) 40 (74.1) 14 (25.5) <0.001a)

Smoking history (N=109) 53 (48.6) 35 (64.8) 18 (32.7) 0.001a)

Low handgrip strength (N=109) 70 (64.2) 34 (63.0) 36 (65.5) 0.786a)

Chronic kidney disease (N=109) 38 (34.9) 19 (35.2) 19 (34.5) 0.944a)

The data is presented as N (%).

a)

Pearson’s χ2 test.

b)

Fisher’s exact test.

NYHA, the New York Heart Association; LVEF, left ventricular ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; HF, heart failure; BMD, bone mineral density; TBS, trabecular bone score.